Blog
AI drug discovery startup is Boston’s latest ‘unicorn’
A Boston biotech has surpassed a $1 billion valuation, making it the fourth company to reach unicorn valuation in as many months.
A Boston biotech has surpassed a $1 billion valuation, making it the fourth company to reach unicorn valuation in as many months.